Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15563296 | 1.00 | HDAC4 (0.55) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL3683654 | 0.88 | CTSK (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL330005 | 0.88 | CTSK (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL1937079 | 0.88 | CTSK (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL1937084 | 0.88 | CTSK (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL330004 | 0.88 | CTSK (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL1935450 | 0.86 | CTSK (0.47) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL13685180 | 0.86 | CTSK (0.47) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL1935453 | 0.86 | CTSK (0.47) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL17600419 | 0.86 | HDAC4 (0.48) | HDAC4HDAC1HDAC6ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882754-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2225249-B1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | HOFFMANN LA ROCHE (CH) | 2016-08-03 | — | — | EP | disclosed |
| EP-2882754-A1 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-06-17 | — | — | EP | disclosed |
| US-8987195-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140057836-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-02-27 | — | — | US | disclosed |
| WO-2014025736-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8106187-B2 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2323981-A1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | F. Hoffmann-La Roche AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7910728-B2 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2150548-B1 | PROCESS FOR HCV PROTEASE INHIBITOR INTERMEDIATE | HOFFMANN LA ROCHE (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-7847106-B2 | Process for the preparation of macrocyclic compounds | ROCHE PALO ALTO LLC (US) | 2010-12-07 | — | — | US | disclosed |
| WO-2010015545-A1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100036116-A1 | Process for the preparation of a macrocycle | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-2150548-A1 | PROCESS FOR HCV PROTEASE INHIBITOR INTERMEDIATE | F. Hoffmann-Roche AG (CH) | 2010-02-10 | — | — | EP | disclosed |
| US-20090163706-A1 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20080269502-A1 | Process for the preparation of macrocyclic compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| WO-2008128921-A1 | PROCESS FOR HCV PROTEASE INHIBITOR INTERMEDIATE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269502-A1 | Process for the preparation of macrocyclic compounds | FURIN, PEPD, CTRL | HDAC4 3093/4885HDAC1 878/4885HDAC6 1431/4885 |
| US-20140057836-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, TMPRSS15, CTSC | HDAC4 2082/4885HDAC1 2151/4885HDAC6 443/4885 |
| US-20090163706-A1 | Process for the preparation of a macrocycle | CTRL, PREP, RNASE1 | HDAC4 3671/4885HDAC1 1502/4885HDAC6 1675/4885 |
| US-20100036116-A1 | Process for the preparation of a macrocycle | CTRL, PREP, RNASE1 | HDAC4 3671/4885HDAC1 1502/4885HDAC6 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.